Clinical Trial Update: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ledipasvir/sofosbuvir fixed-dose combination with and without ribavirin for chronic hepatitis C, completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2015-03-27